@article{discovery10137226,
            year = {2021},
           month = {October},
          volume = {12},
         journal = {Nature Communications},
           title = {Validation of lipid-related therapeutic targets for coronary heart disease prevention using human genetics},
            note = {This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.},
        abstract = {Drug target Mendelian randomization (MR) studies use DNA sequence variants in or near a gene encoding a drug target, that alter the target's expression or function, as a tool to anticipate the effect of drug action on the same target. Here we apply MR to prioritize drug targets for their causal relevance for coronary heart disease (CHD). The targets are further prioritized using independent replication, co-localization, protein expression profiles and data from the British National Formulary and clinicaltrials.gov. Out of the 341 drug targets identified through their association with blood lipids (HDL-C, LDL-C and triglycerides), we robustly prioritize 30 targets that might elicit beneficial effects in the prevention or treatment of CHD, including NPC1L1 and PCSK9, the targets of drugs used in CHD prevention. We discuss how this approach can be generalized to other targets, disease biomarkers and endpoints to help prioritize and validate targets during the drug development process.},
          author = {Gordillo-Mara{\~n}{\'o}n, M and Zwierzyna, M and Charoen, P and Drenos, F and Chopade, S and Shah, T and Engmann, J and Chaturvedi, N and Papacosta, O and Wannamethee, G and Wong, A and Sofat, R and Kivimaki, M and Price, JF and Hughes, AD and Gaunt, TR and Lawlor, DA and Gaulton, A and Hingorani, AD and Schmidt, AF and Finan, C},
             url = {https://doi.org/10.1038/s41467-021-25731-z},
        keywords = {Cardiovascular diseases, Genetics, Target validation}
}